As part of a trading update, management at Nanosonics anticipates the consensus estimate for FY22 revenue will be met. Morgans points out the transition to a direct sales model with GE is on-track.
The sales and clinical applications team has been expanded to meet the end of June transition-completion date. The broker maintains its Add rating and $5.43 target price.
Sector: Health Care Equipment & Services.
Target price is $5.43.Current Price is $3.87. Difference: $1.56 – (brackets indicate current price is over target). If NAN meets the Morgans target it will return approximately 29% (excluding dividends, fees and charges – negative figures indicate an expected loss).
